Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.45 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204743 | 1.00 | CYP2C19 (0.50) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL6542917 | 1.00 | CYP2C19 (0.50) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL326061 | 1.00 | CYP2C19 (0.50) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL5349667 | 1.00 | CYP2C19 (0.50) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL19902117 | 1.00 | CYP2C19 (0.50) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL23366184 | 1.00 | CYP2C19 (0.50) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL375124 | 1.00 | CYP2C19 (0.50) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL4380992 | 0.96 | CYP2C19 (0.47) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL2385417 | 0.96 | CYP2C19 (0.47) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| Bromide SCHEMBL29077840 | 0.96 | CYP2C19 (0.47) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113277510-A | Synthetic method for preparing porous carbon material by using small molecules | 中国科学技术大学 | 2021-08-20 | — | — | CN | claimed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117677603-A | Cyclohexane lipids for nucleic acid transfection and uses thereof | 捷克有机化学和生物化学研究院 | 2024-03-08 | — | — | CN | disclosed |
| CN-113277510-A | Synthetic method for preparing porous carbon material by using small molecules | 中国科学技术大学 | 2021-08-20 | — | — | CN | disclosed |
| US-11007274-B2 | Compounds for medicinal applications | AusVir Therapeutics Pty Ltd (AU) | 2021-05-18 | — | — | US | disclosed |
| US-20180264128-A1 | COMPOUNDS FOR MEDICINAL APPLICATIONS | Australian Biomedical Co. Pty Ltd. (AU) | 2018-09-20 | — | — | US | disclosed |
| US-10030483-B2 | Carbon dioxide and hydrocarbon assisted enhanced oil recovery | GENERAL ELECTRIC COMPANY (US) | 2018-07-24 | — | — | US | disclosed |
| US-9932238-B2 | Graphene and graphene oxide nano-environments for chemical reactions and atomic reformations | PEERLESS WORLDWIDE, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170114269-A1 | CARBON DIOXIDE AND HYDROCARBON ASSISTED ENHANCED OIL RECOVERY | BAKER HUGHES, A GE COMPANY, LLC | 2017-04-27 | — | — | US | disclosed |
| EP-0705279-B1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORP (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20010036517-A1 | Glass-forming liquid crystalline compositions and optical devices formed therefrom | NATIONAL SCIENCE FOUNDATION | 2001-11-01 | — | — | US | disclosed |
| US-6090912-A | MULTIPLICITY OF SEPARATE SOLID SUPPORTS WITH SURFACE HAVING SUCEPTIBLE LINKER TO SINGLE SPECIES OF TEST COMPOUND AND WITH INTERIOR HAVING ATTACHED NON-CLEAVABLE CODING MOLECULE; FOR SCREENING LIGANDS OR ACCEPTORS | SELECTIDE CORPORATION (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0705279-A4 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5840485-A | SYNTHETIC TEST COMPOUNDS ATTACHED TO SEPARATE PHASE SYNTHESIS SUPPORTS THAT ALSO CONTAIN CODING MOLECULES THAT ENCODE THE STRUCTURE OF THE SYNTHETIC TEST COMPOUND | SELECTIDE CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0705279-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1994028028-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0587610-A1 | SPECIFICALLY BETA-BETA CROSS-LINKED HEMOGLOBINS AND METHOD OF PREPARATION | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1994-03-23 | — | — | EP | disclosed |
| US-5250665-A | Artificial blood | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1993-10-05 | — | — | US | disclosed |
| WO-1992021702-A1 | SPECIFICALLY BETA-BETA CROSS-LINKED HEMOGLOBINS AND METHOD OF PREPARATION | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | HAVCR2, ENGASE, DNPEP | CYP2C19 1514/4885GABRR1 2011/4885CYP2D6 533/4885 |
| US-20180264128-A1 | COMPOUNDS FOR MEDICINAL APPLICATIONS | HAVCR2, ENGASE, DNPEP | CYP2C19 1514/4885GABRR1 2011/4885CYP2D6 533/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | CYP2C19 4080/4885GABRR1 2029/4885CYP2D6 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.